Magnesium sulfate tocolysis: Time to quit [2]

Obstetrics and Gynecology

Volumn 109, Issue 2 PART 1, 2007, Pages 450-451

  Macones, George ^a   Hauth, John C ^b   Lockwood, Charles J ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; PLACEBO; UTERUS SPASMOLYTIC AGENT;

DRUG SAFETY; FETUS RISK; HUMAN; INFANT MORTALITY; LETTER; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; SIDE EFFECT; TOCOLYSIS; UNITED STATES; FEMALE; METHODOLOGY; NOTE; TREATMENT OUTCOME;

FEMALE; HUMANS; MAGNESIUM SULFATE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; RESEARCH DESIGN; TOCOLYTIC AGENTS; TREATMENT OUTCOME;

EID: 33846700189     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000244696.81795.3f     Document Type: Letter

References (4)

1. Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 2006;108:986-9.
2. Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997;350:1517-8.
3. Bénichou J, Zupan V, Fernandez H, Marpeau L, Marret S. Tocolytic magnesium sulphate and paediatric mortality. Lancet 1998;351:290-1.
4. Crowther CA, Hiller JE, Doyle LW, Haslam RR, for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290:2669-76.